文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

BNT162b2 mRNA新冠疫苗在HIV-1感染者中的免疫原性与安全性

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
PubMed 文献 · Clin Microbiol Infect · 2021-08-24

该前瞻性开放研究纳入143例HIV-1感染者与261名免疫正常医护人员,评估BNT162b2疫苗接种后的免疫原性与安全性。第二剂后中位18天,98%的感染者抗RBD-IgG阳性,97%血清中和SARS-CoV-2假病毒;不良事件以注射部位疼痛、疲劳和头痛为主,未见AIDS相关不良事件。

要点

  • HIV-1感染者接种BNT162b2后抗RBD-IgG阳性率达98%,中和抗体达97%。
  • 不良事件以注射部位疼痛、疲劳和头痛为主,未见AIDS相关不良事件。
  • 3/143例HIV载量从<40 copies/mL升至≤100 copies/mL,CD4计数几何均值下降。

核心结论

  • BNT162b2 mRNA疫苗在接受抗逆转录病毒治疗、CD4计数未抑制且病毒载量抑制的HIV-1感染者中具有免疫原性和安全性。

研究设计与样本

  • 前瞻性开放研究,纳入143例年龄≥18岁的HIV-1感染者和261名免疫正常医护人员。
  • 检测SARS-CoV-2受体结合域(RBD)IgG和中和抗体,并监测不良事件、病毒载量和CD4细胞计数。

主要发现

  • 第二剂后中位18天(IQR 14-21天),139/141(98%)HIV-1感染者抗RBD-IgG阳性。
  • 医护人员第二剂后中位26天(IQR 24-27天),258/261(98.9%)抗RBD-IgG阳性。
  • 第二剂后,HIV-1感染者和医护人员血清中和SARS-CoV-2假病毒的比例分别为97%和98%。
  • 60%的HIV-1感染者报告不良事件,主要为注射部位疼痛、疲劳和头痛;未报告AIDS相关不良事件。
  • 3/143(2%)患者HIV载量从<40 copies/mL升至≤100 copies/mL;CD4+ T细胞计数几何均值从700 cells/μL(95%CI 648-757 cells/μL)降至633.8 cells/μL(95%CI 588-683 cells/μL)(p < 0.01)。

临床怎么用

  • 对于接受抗逆转录病毒治疗、CD4计数未抑制且病毒载量抑制的HIV-1感染者,BNT162b2疫苗可考虑接种。
  • 接种后需关注注射部位疼痛、疲劳和头痛等不良事件,并监测HIV载量和CD4细胞计数变化。

局限性

  • 本研究为前瞻性开放研究,非随机对照设计。
  • 研究人群限于接受抗逆转录病毒治疗、CD4计数未抑制且病毒载量抑制的HIV-1感染者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with human immunodeficiency virus type 1 (PLWH) are unknown. We aimed to assess the immunogenicity and safety of this vaccine in PLWH. METHODS: In this prospective open study, we enrolled 143 PLWH, aged ≥18 years, who attended our clinic and 261 immunocompetent health-care workers (HCWs). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) IgG and neutralizing antibodies were measured. Adverse events, viral load and CD4 cell counts were monitored. RESULTS: At a median of 18 days (interquartile range 14-21 days) after the second dose, anti-RBD-IgG was positive in 139/141 (98%) PLWH. Among HCWs, 258/261 (98.9%) developed anti-RBD-IgG at a median of 26 days (interquartile range 24-27 days) after the second dose. Following the second dose, immune sera neutralized SARS-CoV-2 pseudo-virus in 97% and 98% of PLWH and HCWs, respectively. Adverse events were reported in 60% of PLWH, mainly pain at the injection site, fatigue and headache. AIDS-related adverse events were not reported. Human immunodeficiency virus load increased in 3/143 (2%) patients from <40 copies/mL to ≤100 copies/mL. CD4+ T-cell count decreased from a geometric mean of 700 cells/μL (95% CI 648-757 cells/μL) to 633.8 cells/μL (95% CI 588-683 cells/μL) (p < 0.01). CONCLUSIONS: BNT162b2 mRNA vaccine appears immunogenic and safe in PLWH who are on antiretroviral therapy with unsuppressed CD4 count and suppressed viral load.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021. PMID: 34438069. doi:10.1016/j.cmi.2021.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。